

## **AstraZeneca Japan to use new ResApp software in lung cancer clinical study**

- **New cough counting application designed to measure frequency of patient coughs over extended period – cough frequency can provide insight into the progression and management of respiratory disease**
- **Software to be licenced to AstraZeneca’s Japanese subsidiary - ResApp to develop application for clinical trial and broader use**
- **Excellent validation of ResApp’s technology from industry-leading pharmaceutical company**

**Brisbane, Australia, 22 October 2020** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that it has built a new smartphone application which has been non-exclusively licenced to AstraZeneca K.K. (“AstraZeneca”), the Japanese subsidiary of global biopharmaceutical company AstraZeneca PLC. for use in a clinical study of lung cancer patients. The app uses ResApp’s proprietary algorithms which count patient coughs over extended periods.

The application is the result of over 12 months development and uses the company’s patent protected technology to identify coughs from background noises in everyday settings. The application records the number of coughs from a patient and uploads the count with a time and date stamp to allow researchers and healthcare professionals to monitor patients in real time.

Cough frequency is a key factor in respiratory disease progression and management. Traditionally, the only ways to measure the occurrences is by subjective self-reporting or manually listening to audio recordings. These methods are labour intensive, not cost effective and fraught with inaccuracy. The cough counting application was developed to deliver patients and healthcare providers more accurate and reliable analysis for disease monitoring.

Under the agreement with AstraZeneca, ResApp will spend the next two months refining the Japanese version of the application to AstraZeneca’s specifications, with an aim to use it in an upcoming clinical trial of patients undergoing treatment for lung cancer. The clinical study is set to commence early next year and run for two years.

AstraZeneca will pay a monthly licence fee for each patient enrolled in the initial study as well as a monthly support fee for the duration of the study. The number of patients in the planned clinical trial and the length of their participation is uncertain. ResApp does not expect to generate material revenue from the initiative.

AstraZeneca is particularly attracted to ResApp’s proprietary technology due to its superior capability to detect and measure cough using only a smartphone, its ability to differentiate between coughs and background noise and its cloud-based reporting functionality.



ResApp is confident that the initial development stages with AstraZeneca and the clinical trial will deliver insights for future product applications. The company is actively exploring opportunities to integrate the technology into a range of hardware devices and existing products, including smart devices. Discussions with large industry partners are underway and ResApp is confident further developments will be made in the coming months.

**Managing Director and CEO Dr Tony Keating said:** *“To have our technology licensed by a company of AstraZeneca’s reputation is a major achievement and provides significant validation of ResApp’s products and capability. They have some of the world’s leading scientists and researchers running clinical trials and treatment programs and we are confident that their input will enhance our technology for future commercial applications and deployments.*

*“ResApp continues to build a strong foundation of commercial partners and this agreement is another example of the company’s ability to attract industry leaders that can assist in rapid scale well into the future.”*

###

### **About ResApp Health Limited**

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx-EU, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

### **Contacts for ResApp Health**

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Vice President, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*